The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the 2025 KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD). The KDOQI work group reviewed the KDIGO guideline statements and practice points and provided perspective for implementation within the context of clinical practice in the United States. In general, the KDOQI work group...

The assessment of body composition has long been a fundamental component of research and is gaining increasing adoption in clinical practice. This growing interest has drawn new professionals to the field and increased emphasis on its clinical relevance and applications. However, the diversity of assessment techniques and inconsistent terminology create challenges, highlighting the urgent need for harmonized approaches across research and healthcare settings. Commonly employed methods include...

Interventions Testing Program identified rapamycin as a robust lifespan-extending agent at multiple testing sites and in both sexes, with particularly strong effects in females, making it a leading candidate in aging research. We used genetically heterogeneous UM-HET3 mice of both sexes to determine whether rapamycin can prevent or delay age-sensitive traits. Mice were supplemented with microencapsulated rapamycin at 14 ppm starting at 12 months of age. Chronic rapamycin supplementation...

CONCLUSION: IUD increases from cephalad to caudad and reduces from anterior to posterior at each level. For the vast majority (regardless of gender/BMI), the IUD is at least 14 mm, especially in the most commonly CDA-treated disc spaces (C5-6, C6-7), suggesting that 14 mm could serve as "one-width" for all CDAs, especially if the primary goal of the surgical technique is to significantly reduce the need for bony resection/burring to create a proper width-fit of the implant.

Senescent cells have been implicated in the pathogenesis of metabolic dysfunction-associated liver disease (MASLD), which can negatively affect female fertility. Senolytic drugs are reported to eliminate senescent cells in various tissues, including the ovary. However, the efficacy of senolytic drugs in reducing liver damage and preserving fertility in female mice with MASLD remains unclear. Therefore, this study aimed to evaluate the protective effect of senolytic drugs on liver damage and...